ARTHQ (Arch Therapeutics) Accumulated Depreciation: $ Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARTHQ Arch Therapeutics Inc ARTHQ
12 GF Score
Price $0.00
View Full Analysis

What is Arch Therapeutics Accumulated Depreciation?

Arch Therapeutics ARTHQ -99.00% 12 Accumulated Depreciation is $ Mil as of Jun. 2024. GuruFocus rates ARTHQ with a GF Score™ of 12/100.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Arch Therapeutics's annual accumulated depreciation increased from Sep. 2021 ($-0.03 Mil) to Sep. 2022 ($-0.03 Mil) and increased from Sep. 2022 ($-0.03 Mil) to Sep. 2023 ($ Mil).

Arch Therapeutics Accumulated Depreciation Related Terms

Arch Therapeutics Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Arch Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Therapeutics Accumulated Depreciation Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.03 -0.03 -0.03 -

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
ARTHQ
12GF Score
Arch Therapeutics Inc ARTHQ
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $ Mil mean?
Arch Therapeutics (ARTHQ) has a Accumulated Depreciation of $ Mil as of Jun. 2024. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Arch Therapeutics and its competitors.
Is Arch Therapeutics' Accumulated Depreciation too high?
Arch Therapeutics' current Accumulated Depreciation is $ Mil. Overall, Arch Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Arch Therapeutics' Accumulated Depreciation compare to GRTSQ and MTEM?
Arch Therapeutics' Accumulated Depreciation of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Arch Therapeutics and its competitors. Arch Therapeutics's current Accumulated Depreciation is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Therapeutics stock overvalued right now?
Arch Therapeutics (ARTHQ) has a current Accumulated Depreciation of $ Mil. The current Accumulated Depreciation is $ Mil. Arch Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Arch Therapeutics (ARTHQ), the current Accumulated Depreciation is $ Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Therapeutics Business Description

Address 235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
12GF Score

Get the complete analysis for ARTHQ

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price